Y. Suruga et al., PREVENTION OF MURINE AIDS DEVELOPMENT BY (R)-9-(2-PHOSPHONYLMETHOXYPROPYL)ADENINE, Journal of acquired immune deficiency syndromes and human retrovirology, 18(4), 1998, pp. 316-322
LP-BM5 murine leukemia virus (MuLV) infection causes severe immunodefi
ciency termed murine AIDS (MAIDS). The acyclic nucleoside phosphonates
(R)-9-(2-phosphonylmethosypropyl)adenine (PMPA) and 9-(2-phosphonylme
thoxyethyl)adenine (PMEA) were examined, in comparison with zidovudine
(AZT), for their inhibitory effect on the development of MAIDS. Altho
ugh no significant difference in inhibition of LP-BM5 MuLV replication
was identified between PMPA and PMEA in cell cultures, PMPA was obvio
usly less cytotoxic to the host lymphocytes. None of the mice treated
in vivo with 5 or 25 mg/kg of PMPA or 25 mg/kg of PMEA developed MAIDS
at 5 weeks after viral infection. However at 9 weeks, none of the 25
mg/kg PMPA-treated mice progressed to MAIDS? except for one that devel
oped mild MAIDS, whereas PMEA, even at 100 mg/kg, could not prevent di
sease progression. MAIDS-associated activation of lymphocytes and vira
l replication were drastically inhibited by PMPA treatment. These resu
lts indicate that PMPA is a highly effective antiretroviral agent in v
ivo.